USUnited StatesHealthtentative
PDUFA date: Mim8 (Novo Nordisk, hemophilia A) and brepocitinib (Pfizer/Priovant, dermatomyositis)
FDA decisions on two candidates with strong commercial potential at quarter's end.
- News
- 2/5
- Markets
- 4/5
- Overall
- 3/5

